Department of Physiotherapy, LIM-54, Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 455 room 1150, São Paulo, São Paulo, 01246-930, Brazil.
Dante Pazzanese Institute of Cardiology São Paulo State, São Paulo, Brazil.
Sci Rep. 2020 Dec 3;10(1):21112. doi: 10.1038/s41598-020-78242-0.
Several circulating miRNAs identified in the plasma of smokers have been implicated as promoters of nasopharyngeal and lung carcinoma. To investigate the plasma profile of miRNAs in subjects who reduces the number of smoked cigarettes and who quit after six months. We accompanied 28 individuals enrolled in a Smoking Cessation Program over 6 months. At Baseline, clinical characteristics, co-morbidities, and smoking history were similar among subjects. After 6 months, two groups were defined: who successfully quitted smoking (named "quitters", n = 18, mean age 57 years, 11 male) and who reduced the number of cigarettes smoked (20-90%) but failed to quit smoking (named "smokers", n = 10, mean age 52 years, 3 male). No significant clinical changes were observed between groups at baseline and after a 6-month period, however, quitters showed significant downregulations in seven miRNAs at baseline: miR-17 (- 2.90-fold, p = 0.029), miR-20a (- 3.80-fold, p = 0.021); miR-20b (- 4.71-fold, p = 0.027); miR-30a (- 3.95-fold, p = 0.024); miR-93 (- 3.63-fold, p = 0.022); miR-125a (- 1.70-fold, p = 0.038); and miR-195 (- 5.37-fold, p = 0.002), and after a 6-month period in 6 miRNAs: miR-17 (- 5.30-fold, p = 0.012), miR-20a (- 2.04-fold, p = 0.017), miR-20b (- 5.44-fold, p = 0.017), miR-93 (- 4.00-fold, p = 0.041), miR-101 (- 4.82-fold, p = 0.047) and miR-125b (- 3.65-fold, p = 0.025). Using time comparisons, only quitters had significant downregulation in miR-301b (- 2.29-fold, p = 0.038) after 6-month. Reductions in the number of smoked cigarettes was insufficient to change the plasma profile of miRNA after 6 months. Only quitting smoking (100% reduction) significantly downregulated miR-301b related to hypoxic conditions, promotion of cell proliferation, decreases in apoptosis, cancer development, and progression as increases in radiotherapy and chemotherapy resistance.
一些在吸烟者血浆中发现的循环 miRNA 已被认为是促进鼻咽癌和肺癌的因素。为了研究在减少吸烟量和戒烟 6 个月后的受试者血浆中 miRNA 的谱。我们对 28 名参加戒烟计划的个体进行了 6 个月的随访。在基线时,受试者的临床特征、合并症和吸烟史相似。6 个月后,将两组定义为:成功戒烟者(命名为“戒烟者”,n=18,平均年龄 57 岁,男性 11 人)和减少吸烟量(20-90%)但未能戒烟者(命名为“吸烟者”,n=10,平均年龄 52 岁,男性 3 人)。两组在基线和 6 个月期间均无显著临床变化,但戒烟者在基线时有 7 种 miRNA 显著下调:miR-17(-2.90 倍,p=0.029),miR-20a(-3.80 倍,p=0.021);miR-20b(-4.71 倍,p=0.027);miR-30a(-3.95 倍,p=0.024);miR-93(-3.63 倍,p=0.022);miR-125a(-1.70 倍,p=0.038);6 个月后有 6 种 miRNA 下调:miR-17(-5.30 倍,p=0.012),miR-20a(-2.04 倍,p=0.017),miR-20b(-5.44 倍,p=0.017),miR-93(-4.00 倍,p=0.041),miR-101(-4.82 倍,p=0.047)和 miR-125b(-3.65 倍,p=0.025)。使用时间比较,只有戒烟者在 6 个月后 miR-301b 显著下调(-2.29 倍,p=0.038)。减少吸烟量在 6 个月后不足以改变 miRNA 的血浆谱。只有戒烟(100%减少)才能显著下调与低氧条件、细胞增殖促进、细胞凋亡减少、癌症发展和进展相关的 miR-301b,以及增加放射治疗和化疗耐药性。